How much does antibody drug conjugation cost?

ADC conjugation typically costs a few thousand dollars. Pricing depends on: Required quantity Antibody format Need for antibody engineering Whether ProteoGenix supplies the payload Payload nature

How long does ADC development take?

Our standard timeline ranges from 3 to 6 weeks.

Can ProteoGenix generate the starting antibody?

Absolutely. We are experts in custom antibody development and can generate your lead antibody from scratch. For ADCs, a fully human antibody is often recommended. We offer two dedicated discovery platforms: Phage display service using proprietary human libraries (naive, cancer patient–derived, autoimmune patient–derived) Single B cell screening service combined with immunization of humanized mice We also offer off-the-shelf antibodies compatible with conjugation.

Can you optimize an existing antibody for ADC development?

Yes! Our optimization services include: AI-driven affinity maturation Humanization Developability optimization Antibody engineering for conjugation compatibility, especially for enzymatic approaches

Do you offer transient or stable cell line production?

Yes. ProteoGenix provides a complete continuum of recombinant expression solutions, from rapid screening to large-scale manufacturing. Our capabilities include: A high throughput antibody production platform designed for fast candidate evaluation A transient antibody expression service delivering milligram- to gram-scale material on short timelines A full stable cell line development service for projects requiring long-term, scalable manufacturing

Do you provide backup strategies if the selected format is incompatible with conjugation?

Of course. Your project’s success is our priority. Thanks to our broad toolbox, we always propose an alternative strategy when needed.

Antibody Drug Conjugate (ADC) Services

High control ADCs for real-world therapeutic development

Get your quote

Conjugation technologies

3 weeks

From antibody to ADC

>90%

DAR homogeneity

Two conjugation technologies to power every ADC challenge, from proof of concept to clinical-ready material

ProteoGenix offers an extensive portfolio of chemical and enzymatic conjugation solutions. We help you select the optimal strategy based on key criteria such as:

- Antibody structure
- Payload properties
- Scale-up requirements
- Regulatory constraints

Whether you’re validating a concept or preparing for clinical phases, our experts and versatile conjugation toolbox ensure the most suitable solution for your program.

Convert any antibody format into a potent ADC

Our platform supports all antibody formats, from VHHs to IgGs, including Fabs, scFvs, and bispecific antibodies.

Conjugate your antibody

Case report

Discover how controlled ADC conjugation delivered a high-quality Vc-MMAE antibody-drug conjugate to support ovarian cancer proof-of-concept studies.

Case Report: Helping an Australian University Advance Ovarian Cancer Proof-of-Concept Studies with a Characterized ADC.

Read the case report

Achieve controlled toxicity profiles

Perfectly controlled Drug-to-Antibody Ratio (DAR)

Our chemical and enzymatic conjugation technologies are designed to deliver >90% DAR homogeneity at the ratio you specify.
This tight DAR control, and its distribution, is essential for reducing ADC toxicity and avoiding the site-barrier effect.

Broad selection of linkers and payloads

Choose from a wide panel of cleavable and non-cleavable linkers, with expert guidance to ensure:

High stability in circulation to prevent premature payload release
Fast and targeted payload release inside the tumor cells

We also offer an extensive selection of payloads to tailor the optimal DAR/linker/payload configuration for your therapeutic objective.

Get a complete ADC characterization package

We provide a full analytical suite, including: DAR, DAR distribution, drug location, % free drug, and all standard antibody QC measurements.

More reasons to choose ProteoGenix for your ADC development

A true end-to-end partner

From antibody generation to conjugation, we support every step. This integrated approach lets us also fine-tune antibody affinity and kinetics, two critical factors that directly impact your ADC’s therapeutic success.
ISO 9001:2015 certified

Our ISO 9001:2015 certification ensures controlled, standardized, and traceable processes across all stages of your project.
Expert scientific guidance

Because ADC development requires deep expertise, you are supported by dedicated PhD account managers throughout the project.
DAR control without antibody engineering

Our chemical conjugation process allows DAR control even without prior antibody engineering.

Get more information

Tool

Download our dynamic and interactive checklist to thoroughly assess your antibody’s readiness across general criteria and specialized formats.

Download now

ProteoGenix’s ADC development workflow – From your antibody to your ADC in 3 weeks

From your antibody to your ADC in 3 weeks (does not include the optional steps)

Antibody selection (optional)

Customer provides the antibody

Custom antibody generation (any species or format, including custom fully human antibodies)

Antibody optimization (optional)

AI-powered affinity maturation
Developability optimization
Antibody engineering to match the selected conjugation strategy

Antibody conjugation

Selection of the optimal antibody/linker/payload combination
Chemical or enzymatic conjugation

ADC characterization

DAR
DAR distribution
Additional QC analyses

ProteoGenix in the scientific literature

Publications

Lindland, K., Malenge, M. M., & al. (2024). Antigen targeting and anti-tumor activity of a novel anti-CD146 ²¹²Pb internalizing alpha-radioimmunoconjugate against malignant peritoneal mesothelioma. Scientific Reports, 14, 25941.

See the publication

Publications

Rioja-Blanco, E., Banz, Y., Schlapbach, & al. (2025). ¹⁶¹Tb Radioimmunotherapy as a Treatment for CD30-Positive Lymphomas. Journal of Nuclear Medicine, 66(6), 909–915.

See the publication

FAQ about our ADC development service

ADC conjugation typically costs a few thousand dollars. Pricing depends on:
- Required quantity
- Antibody format
- Need for antibody engineering
- Whether ProteoGenix supplies the payload
- Payload nature
Absolutely. We are experts in custom antibody development and can generate your lead antibody from scratch.
For ADCs, a fully human antibody is often recommended.
We offer two dedicated discovery platforms:
- Phage display service using proprietary human libraries (naive, cancer patient–derived, autoimmune patient–derived)
- Single B cell screening service combined with immunization of humanized mice
We also offer off-the-shelf antibodies compatible with conjugation.
Yes! Our optimization services include:
- AI-driven affinity maturation
- Humanization
- Developability optimization
- Antibody engineering for conjugation compatibility, especially for enzymatic approaches
Yes. ProteoGenix provides a complete continuum of recombinant expression solutions, from rapid screening to large-scale manufacturing. Our capabilities include:
- A high throughput antibody production platform designed for fast candidate evaluation
- A transient antibody expression service delivering milligram- to gram-scale material on short timelines
- A full stable cell line development service for projects requiring long-term, scalable manufacturing